# IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

> **NCT05039801** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 54 (estimated)

## Conditions studied

- Advanced Endometrial Carcinoma
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Malignant Solid Neoplasm
- Advanced Melanoma
- Advanced Ovarian Clear Cell Adenocarcinoma
- Chondrosarcoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Refractory Endometrial Carcinoma
- Refractory Head and Neck Squamous Cell Carcinoma
- Refractory Melanoma
- Refractory Ovarian Clear Cell Adenocarcinoma
- Refractory Ovarian High Grade Serous Adenocarcinoma
- Stage III Ovarian Cancer AJCC v8
- Stage III Uterine Corpus Cancer AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA Uterine Corpus Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Uterine Corpus Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IIIC Uterine Corpus Cancer AJCC v8
- Stage IIIC1 Uterine Corpus Cancer AJCC v8
- Stage IIIC2 Uterine Corpus Cancer AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Uterine Corpus Cancer AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Uterine Corpus Cancer AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Glutaminase-1 Inhibitor IACS-6274
- **DRUG:** Paclitaxel
- **DRUG:** Capivasertib

## Key facts

- **NCT ID:** NCT05039801
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-09
- **Primary completion:** 2026-05-29
- **Final completion:** 2026-05-29
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039801, "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05039801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*